Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

CDC advisory committee recommends additional vaccine dose for immunocompromised

The panel referred to the third dose as part of a primary series of vaccination for certain patients.

By Brian Buntz | August 13, 2021

CDC COVID-19The panel joined FDA in endorsing a third dose of Pfizer-BioNTech and Moderna vaccines for moderately to severely immunocompromised patients.

The Advisory Committee on Immunization Practices (ACIP) concluded there was insufficient evidence to recommend an additional dose for immunocompromised recipients of Janssen’s COVID-19 vaccine.

The ACIP panel described the third dose of vaccine as part of a primary series of shots rather than a booster. Moderately to severely immunocompromised patients ages 12 and older would be eligible for a third dose of the Pfizer-BioNTech vaccine. The eligibility criteria for Moderna vaccine recipients is similar but applies to those 18 and older.

The immunocompromised persons described in the recommendation have an increased risk of hospitalization, breakthrough disease and death from COVID-19.

The ACIP shared the FDA’s recommendation of a third dose for patients who had undergone solid organ transplantation or who were diagnosed with conditions leading to a similar impairment of immune function.

ACIP member Dr. Helen Keipp Talbot explained that stance by noting that the recommendation applies to “a very specific population in the U.S. who was not able to mount an appropriate immune response to the normal two doses.” She added: “This is a very specific population, and [the recommendation] is not meant for the entire U.S. population.”

Other patients who would be eligible include those with have received CAR-T cell or hematopoietic stem cell transplants and those with moderate to severe primary immunodeficiency or advanced or untreated HIV. Patients receiving high doses of corticosteroids or other immunosuppressing drugs would also be eligible.

Talbot stressed the importance of sharing vaccine doses worldwide and proactively addressing areas with low vaccination rates.

The Global Liver Institute (GLI) applauded the decisions from the FDA and CDC’s Advisory Committee on Immunization Practices. “This is great news for the seven million immunocompromised Americans, many of whom had no to little protective immune response to the standard one- and two-dose vaccine regimens and so faced risks similar to those who had chosen to take no vaccination at all, or worse, since COVID-19 infection raises our risks of severe effects from infection, including hospitalization and death,” said GLI CEO and President Donna R. Cryer, in a statement. 

In the U.S., the Delta variant has sparked a dramatic increase in COVID-19 infections. The volume of cases has increased 700% since July 1.

 


Filed Under: Infectious Disease
Tagged With: BioNTech, CDC, coronavirus, covid-19, COVID-19 vaccine, COVID-19 vaccine trial, COVID-19 vaccines, FDA, Moderna, Pfizer
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Secretary of Health removes all current members of the CDC advisory committee on immunization practices
covid-19 vaccine
FDA COVID booster pullback jolts vaccine stocks before gains cool
Coronavirus Covid-19 background - 3d rendering
Pregnancy associated with less long COVID: Researchers call for studies on protective biology
How technology advances are helping scientists unlock the mysteries of zoonotic diseases
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE